InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,073.97
(
0.07%
)
US TECH 100
17,066.00
(
0.37%
)
Dow Jones
38,493.20
(
-0.03%
)
Brent Oil
87.27
(
-0.34%
)
Bitcoin
64,370.56
(
-3.07%
)
Post# of 97237
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

ash111

Send PM Follow Ignore
Followers 1055
Posts 189434
Boards Moderated 1
Alias Born 06/19/2009

ash111

Re: None

Friday, 10/13/2017 3:16:22 PM

Friday, October 13, 2017 3:16:22 PM

Post# of 97237
Merck ONCS Partnership was reported by Merck & Co. Inc. itself (which is very primed, if you ask me): https://www.gurufocus.com/news/518583/merck-collaborates-with-oncosec-medical-to-unlock-untapped-market-for-keytruda-

"Under the agreement, OncoSec will sponsor and fund the study and Merck will provide KEYTRUDA". KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
ImmunoPulse® is a registered trademark of OncoSec Medical Incorporated, San Diego, CA, USA.

$ONCS Anticipated Study Start Date:
October 15, 2017
https://www.clinicaltrials.gov/ct2/show/NCT03132675?term=NCT03132675.&rank=1

My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up